Platelet Rich Plasma Market Size, Share And Global Trend By Origin (Allogeneic, Autologous, Homologous), By Type (Pure PRP, Leukocyte rich PRP, Leukocyte rich fibrin), By Application (Orthopaedic surgery, Cosmetic surgery, General surgery, Neurosurgery, Others), And Geography Forecast Till 2030
KEY MARKET INSIGHTS
Platelets are blood cells that help the body to form blood clots to halt bleeding and generated in the bone marrow along with white and red blood cells. Microscopic view of the platelets is like a tiny plate. A normal count of platelet is 150,000 to 450,000 platelets per microliter of blood. Platelet rich plasma (PRP), is a composed of high concentration of platelet rich plasma protein acquired from whole blood and centrifuged to differentiate between plasma and blood cells. PRP has several uses such as tissue healing, hair growth, inflammation reduction and others.
Rise in the use of platelet rich plasma for the treatment of chronic diseases such as orthopaedic diseases, cardiovascular & neurovascular diseases, general surgery, wound management and the increase in demand of the cosmetic surgeries is expected to drive the growth of the global PRP market. Growing geriatric population, increase in the occurrence of orthopaedic and sports injuries, combined with rising adoption of PRP as effective treatment option is one of the factors expanding the growth of the global PRP market.
To gain extensive insights into the market, Request for Customization
However, poor quality control of test results, high cost of the PRP kits, nerve injuries to the patients and tissue damage at the time of treatment are some of the major factors restraining the growth of the global PRP market.
Key Players Covered
Some of the major companies that are present in the global platelet rich plasma market are Arthrex, Inc., Zimmer Biomet, Harvest Technologies Corporation, DePuy Synthes, Inc., Stryker Corporation, AdiStem Ltd., ISTO Biologics, Cesca Therapeutics, Inc., Exactech Inc., Nuo Therapeutics and others.
SEGMENTATION
SEGMENTATION | DETAILS |
By Origin | · Allogeneic · Autologous · Homologous |
By Type | · Pure PRP · Leukocyte rich PRP · Leukocyte rich fibrin |
By Application | · Orthopaedic surgery · Cosmetic surgery · General surgery · Neurosurgery · Others |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
Among the segmentation of application, the orthopaedic surgery is estimated to hold a major proportion in the global PRP market owing to the high prevalence of the disease.
Key Insights
Pipeline analysis
Pricing analysis
Key mergers and acquisitions
Technological advancements
Regional Analysis
The global PRP market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America is projected to hold the highest position in the global PRP market due to a rise in the demand for cosmetic surgeries, high prevalence of orthopaedic surgeries and an increase in sports injuries. According to Arthritis Foundation, in North America 54 million adults and around 300,000 children were diagnosed of arthritis in 2017, this has increased the demand of the PRP treatment is further anticipated to fuel the growth of the global PRP market. Asia Pacific is projected to expand the global PRP market at significant CAGR in the forecast period due to the large patient pool with various rheumatology disorders, rise in a number of sport injury cases and increase in demand of cosmetic surgeries in emerging countries such as India and China.
Key Industry Developments
- In July 2017, Regenexx completed the acquisition of Harbor View Medical Services.
- In May 2019, Estar Technologies Ltd. announced that the European Patent Office has revoked the patent of Regen Lab SA’s Platelet Rich Plasma (PRP) patent due to lack of novelty.
- In February 2014, ThermoGenesis Corp. received stockholder approval for acquisition of TotipotentRX Cell Therapy Pvt. Ltd.
- In September 2016, Alliance Partners, LLC received 510(k) approval from the U.S Food and Drug Administration for the company’s Cyclone Platelet Rich Plasma (PRP) Concentrating System
- Ongoing
- 2022
- 2019-2021
Personalize this Research
- Granular Research on Specified Regions or Segments
- Companies Profiled based on User Requirement
- Broader Insights Pertaining to a Specific Segment or Region
- Breaking Down Competitive Landscape as per Your Requirement
- Other Specific Requirement on Customization
Healthcare Clients
